We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+8.78%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.32B
AUM Growth
-$52.2M
Cap. Flow
-$44.2M
Cap. Flow %
-1.9%
Top 10 Hldgs %
73.45%
Holding
41
New
1
Increased
16
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$20.8M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$19.8M
3
INSM icon
Insmed
INSM
+$6.88M
4
EPZM
Epizyme, Inc
EPZM
+$6.72M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.16M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$65.3M
2
UTHR icon
United Therapeutics
UTHR
+$19.9M
3
FOLD
Amicus Therapeutics
FOLD
+$19.4M
4
EXAS
Exact Sciences
EXAS
+$6.52M
5
AIMT
Aimmune Therapeutics
AIMT
+$4.75M

Sector Composition

Rank Sector Weight
1 Healthcare 92.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
1
DELISTED
Abiomed Inc
ABMD
$297M 12.8%
1,585,413
-349,887
-18% -$65.3M
UTHR icon
2
United Therapeutics
UTHR
$23.1B
$238M 10.23%
1,606,250
-156,400
-9% -$19.9M
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
$231M 9.97%
3,402,781
+73,200
+2% +$5.12M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$12.4B
$223M 9.59%
2,497,806
+59,287
+2% +$5.16M
INSM icon
5
Insmed
INSM
$28.6B
$200M 8.6%
6,404,586
+232,770
+4% +$6.88M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$134M 5.76%
1,117,642
+37,300
+3% +$4.54M
SAGE
7
DELISTED
Sage Therapeutics
SAGE
$134M 5.75%
810,806
+23,555
+3% +$2.28M
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
$86.4M 3.72%
6,006,022
-1,414,266
-19% -$19.4M
EPZM
9
DELISTED
Epizyme, Inc
EPZM
$86.1M 3.71%
6,860,843
+462,547
+7% +$6.72M
IMMU
10
DELISTED
Immunomedics Inc
IMMU
$77.2M 3.32%
4,774,261
+1,763,795
+59% +$20.8M
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$302M
$63.2M 2.72%
4,155,670
– –
WMGI
12
DELISTED
Wright Medical Group Inc
WMGI
$60.7M 2.62%
2,736,293
+59,900
+2% +$1.48M
STAA icon
13
STAAR Surgical
STAA
$1.21B
$54.2M 2.33%
3,496,752
-10,300
-0.3% -$153K
ACAD icon
14
Acadia Pharmaceuticals
ACAD
$5.03B
$49.4M 2.13%
1,641,030
– –
ALGN icon
15
Align Technology
ALGN
$12.3B
$47.2M 2.03%
212,507
-10,600
-5% -$2.41M
AMAG
16
DELISTED
AMAG Pharmaceuticals
AMAG
$46.3M 1.99%
3,493,220
+51,987
+2% +$784K
AIMT
17
DELISTED
Aimmune Therapeutics
AIMT
$43.4M 1.87%
1,146,419
-147,345
-11% -$4.75M
PRTA icon
18
Prothena Corp
PRTA
$450M
$41.1M 1.77%
1,095,655
– –
KPTI icon
19
Karyopharm Therapeutics
KPTI
$48M
$34M 1.47%
236,296
+3,057
+1% +$491K
CELG
20
DELISTED
Celgene Corp
CELG
$32.1M 1.38%
307,940
+12,700
+4% +$1.43M
MNTA
21
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$25.4M 1.09%
1,821,576
+26,578
+1% +$359K
ALDR
22
DELISTED
Alder Biopharmaceuticals
ALDR
$21.1M 0.91%
1,840,246
+1,775,846
+2,758% +$19.8M
SHPG
23
DELISTED
Shire pic
SHPG
$21.1M 0.91%
135,800
+5,600
+4% +$830K
EXAS
24
DELISTED
Exact Sciences
EXAS
$16.3M 0.7%
310,876
-122,200
-28% -$6.52M
RIGL icon
25
Rigel Pharmaceuticals
RIGL
$750M
$15.3M 0.66%
393,558
+8,056
+2% +$307K
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q4 2017 Portfolio in Review

As of Q4 2017, Palo Alto Investors held 41 positions worth $2.32B, down 2.2% from $2.37B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Palo Alto Investors's Q4 2017 filing shows 1 new, 16 increased, 7 reduced and 4 closed positions. Its largest new stake was Melinta Therapeutics, Inc. Common Stock: 10,138 shares worth $801K. The largest sale was Abiomed Inc, an estimated $65.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier.

  • Palo Alto Investors's largest Q4 2017 buy was Melinta Therapeutics, Inc. Common Stock: 10,138 shares worth $801K.
  • Palo Alto Investors added most to Immunomedics Inc in Q4 2017, an estimated $20.8M increase.
  • Palo Alto Investors's biggest Q4 2017 reduction was Abiomed Inc, cutting an estimated $65.3M.
  • Palo Alto Investors fully exited Talphera in Q4 2017, selling an estimated $4.75M.
  • Palo Alto Investors's ten largest holdings make up 73% of its $2.32B portfolio in Q4 2017.
  • Palo Alto Investors opened 1 new position and closed 4 in Q4 2017.
  • Palo Alto Investors's portfolio value fell 2.2% quarter-over-quarter to $2.32B.

Based on Palo Alto Investors's 13F filing for Q4 2017, filed 14 Feb 2018.